Navigating the Challenge of CNS Metastases in TNBC Patients

The chapter delves into the complex case of a triple-negative breast cancer patient who experienced a full pathological response but later developed brain metastasis, highlighting the intricacies in determining treatment duration for patients without active disease. Speakers explore the potential of PARP inhibitors in treating CNS metastases in patients with BRCA mutations, discussing therapy tolerability, duration, and efficacy compared to traditional chemotherapy. The conversation also delves into ongoing trials with neoadjuvant PARP inhibitors for BRCA mutation carriers, raising questions about the role of chemotherapy and the need for effective biomarkers to predict treatment response.